HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.
Several recent large clinical trials evaluated HIV vaccine candidates that were based on recombinant adenovirus serotype 5 (rAd-5) vectors expressing HIV-derived antigens. These vaccines primarily elicited T-cell responses, which are known to be critical for controlling HIV infection. In the current...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/65453933a1c548b5b4a92a58148c1113 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:65453933a1c548b5b4a92a58148c1113 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:65453933a1c548b5b4a92a58148c11132021-11-18T06:05:30ZHIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.1553-73661553-737410.1371/journal.ppat.1003404https://doaj.org/article/65453933a1c548b5b4a92a58148c11132013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23818843/?tool=EBIhttps://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Several recent large clinical trials evaluated HIV vaccine candidates that were based on recombinant adenovirus serotype 5 (rAd-5) vectors expressing HIV-derived antigens. These vaccines primarily elicited T-cell responses, which are known to be critical for controlling HIV infection. In the current study, we present a meta-analysis of epitope mapping data from 177 participants in three clinical trials that tested two different HIV vaccines: MRKAd-5 HIV and VRC-HIVAD014-00VP. We characterized the population-level epitope responses in these trials by generating population-based epitope maps, and also designed such maps using a large cohort of 372 naturally infected individuals. We used these maps to address several questions: (1) Are vaccine-induced responses randomly distributed across vaccine inserts, or do they cluster into immunodominant epitope hotspots? (2) Are the immunodominance patterns observed for these two vaccines in three vaccine trials different from one another? (3) Do vaccine-induced hotspots overlap with epitope hotspots induced by chronic natural infection with HIV-1? (4) Do immunodominant hotspots target evolutionarily conserved regions of the HIV genome? (5) Can epitope prediction methods be used to identify these hotspots? We found that vaccine responses clustered into epitope hotspots in all three vaccine trials and some of these hotspots were not observed in chronic natural infection. We also found significant differences between the immunodominance patterns generated in each trial, even comparing two trials that tested the same vaccine in different populations. Some of the vaccine-induced immunodominant hotspots were located in highly variable regions of the HIV genome, and this was more evident for the MRKAd-5 HIV vaccine. Finally, we found that epitope prediction methods can partially predict the location of vaccine-induced epitope hotspots. Our findings have implications for vaccine design and suggest a framework by which different vaccine candidates can be compared in early phases of evaluation.Tomer HertzHasan AhmedDavid P FriedrichDanilo R CasimiroSteven G SelfLawrence CoreyM Juliana McElrathSusan BuchbinderHelen HortonNicole FrahmMichael N RobertsonBarney S GrahamPeter GilbertPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 9, Iss 6, p e1003404 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 |
| spellingShingle |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Tomer Hertz Hasan Ahmed David P Friedrich Danilo R Casimiro Steven G Self Lawrence Corey M Juliana McElrath Susan Buchbinder Helen Horton Nicole Frahm Michael N Robertson Barney S Graham Peter Gilbert HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| description |
Several recent large clinical trials evaluated HIV vaccine candidates that were based on recombinant adenovirus serotype 5 (rAd-5) vectors expressing HIV-derived antigens. These vaccines primarily elicited T-cell responses, which are known to be critical for controlling HIV infection. In the current study, we present a meta-analysis of epitope mapping data from 177 participants in three clinical trials that tested two different HIV vaccines: MRKAd-5 HIV and VRC-HIVAD014-00VP. We characterized the population-level epitope responses in these trials by generating population-based epitope maps, and also designed such maps using a large cohort of 372 naturally infected individuals. We used these maps to address several questions: (1) Are vaccine-induced responses randomly distributed across vaccine inserts, or do they cluster into immunodominant epitope hotspots? (2) Are the immunodominance patterns observed for these two vaccines in three vaccine trials different from one another? (3) Do vaccine-induced hotspots overlap with epitope hotspots induced by chronic natural infection with HIV-1? (4) Do immunodominant hotspots target evolutionarily conserved regions of the HIV genome? (5) Can epitope prediction methods be used to identify these hotspots? We found that vaccine responses clustered into epitope hotspots in all three vaccine trials and some of these hotspots were not observed in chronic natural infection. We also found significant differences between the immunodominance patterns generated in each trial, even comparing two trials that tested the same vaccine in different populations. Some of the vaccine-induced immunodominant hotspots were located in highly variable regions of the HIV genome, and this was more evident for the MRKAd-5 HIV vaccine. Finally, we found that epitope prediction methods can partially predict the location of vaccine-induced epitope hotspots. Our findings have implications for vaccine design and suggest a framework by which different vaccine candidates can be compared in early phases of evaluation. |
| format |
article |
| author |
Tomer Hertz Hasan Ahmed David P Friedrich Danilo R Casimiro Steven G Self Lawrence Corey M Juliana McElrath Susan Buchbinder Helen Horton Nicole Frahm Michael N Robertson Barney S Graham Peter Gilbert |
| author_facet |
Tomer Hertz Hasan Ahmed David P Friedrich Danilo R Casimiro Steven G Self Lawrence Corey M Juliana McElrath Susan Buchbinder Helen Horton Nicole Frahm Michael N Robertson Barney S Graham Peter Gilbert |
| author_sort |
Tomer Hertz |
| title |
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| title_short |
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| title_full |
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| title_fullStr |
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| title_full_unstemmed |
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. |
| title_sort |
hiv-1 vaccine-induced t-cell responses cluster in epitope hotspots that differ from those induced in natural infection with hiv-1. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/65453933a1c548b5b4a92a58148c1113 |
| work_keys_str_mv |
AT tomerhertz hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT hasanahmed hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT davidpfriedrich hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT danilorcasimiro hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT stevengself hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT lawrencecorey hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT mjulianamcelrath hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT susanbuchbinder hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT helenhorton hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT nicolefrahm hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT michaelnrobertson hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT barneysgraham hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 AT petergilbert hiv1vaccineinducedtcellresponsesclusterinepitopehotspotsthatdifferfromthoseinducedinnaturalinfectionwithhiv1 |
| _version_ |
1718424607554273280 |